Cognition Therapeutics In... (CGTX)
0.76
0.05 (7.04%)
At close: Jan 28, 2025, 2:39 PM
undefined% (undefined)
| Bid | 0.76 |
| Market Cap | 31.37M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.96 |
| PE Ratio (ttm) | -0.79 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.76 |
| Volume | 562,600 |
| Avg. Volume (20D) | 7,789,735 |
| Open | 0.73 |
| Previous Close | 0.71 |
| Day's Range | 0.72 - 0.76 |
| 52-Week Range | 0.34 - 2.95 |
| Beta | undefined |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinica...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol CGTX
Website https://www.cogrx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CGTX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 1092.05% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
1 month ago
+9.31%
Cognition Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
1 month ago
+27.5%
Cognition Therapeutics shares are trading higher after the company announced topline results which met its primary endpoint of safety and tolerability from its exploratory Phase 2 SHIMMER study.
